STAA
HoldPremium GrowerSTAAR Surgical Company · Healthcare · United States · $1.1B · Avg Vol: $22M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
ABOUT STAAR SURGICAL COMPANY
Read
STAAR Surgical Company designs, develops, manufactures, and markets implantable lenses for the eye, primarily its proprietary EVO Visian Implantable Collamer Lens (ICL) for vision correction. The company holds a leadership position in the premium refractive vision correction market due to its unique, patented ICL technology offering superior visual outcomes for suitable patients. It benefits from high barriers to entry in ophthalmology and growing market acceptance of its advanced lens solutions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 284.4M | 322.4M | 313.9M | 239.4M | -5.6% | 339.6M | 334.6M | 361.0M | 14.7% |
| EPS | 0.81 | 0.44 | -0.41 | -1.62 | -45.7% | 0.08 | — | — | — |
| Shares | 48.2M | 48.8M | 49.3M | 49.4M | +2.5% | 50.1M | — | — | — |
| Debt | 31.0M | 35.8M | 38.7M | 38.4M | 7.3% | 35.9M | — | — | — |
| Equity | 336.1M | 386.0M | 397.3M | 344.2M | 0.8% | — | — | — | — |
| Op CF | 35.7M | 14.6M | 15.7M | -34.2M | -33.6% | -3.3M | — | — | — |
| Inv CF | -156.4M | 74.3M | -59.2M | 46.3M | — | — | — | — | — |
| Fin CF | 8.3M | 7.4M | 5.7M | -4.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STAA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| STAA | STAAR Surgical Company(you) | $1.1B | 57 | Hold |
| LMAT | LeMaitre Vascular, Inc. | $1.8B | 53 | Hold |
| XRAY | DENTSPLY SIRONA Inc. | $2.2B | 58 | Hold |
| ANGO | AngioDynamics, Inc. | $655M | 52 | Hold |
| AZTA | Azenta, Inc. | $1.4B | 46 | Hold |
| BLFS | BioLife Solutions, Inc. | $1.8B | 50 | Hold |
| ATRC | AtriCure, Inc. | $2.5B | 64 | Hold |
| ICUI | ICU Medical, Inc. | $4.4B | 63 | Hold |
| SMTI | Sanara MedTech Inc. | $318M | 68 | Buy |
| KMTS | Kestra Medical Technologies, Ltd. | $1.5B | 26 | Sell |
Peer medians: ROE -31.0% · P/E 25.0x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.